uniQure saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 89 to 92.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique rating measures price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 at the beginning of a new run.
uniQure is working on a consolidation with a 17.60 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.
The company posted 0% EPS growth in its most recent report. Sales rose -53%.
The company holds the No. 144 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Rigel Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
